ACE2
COVID-19
SARS-CoV-2
drugs repositioning
virus entry inhibitors
Journal
Journal of biomolecular structure & dynamics
ISSN: 1538-0254
Titre abrégé: J Biomol Struct Dyn
Pays: England
ID NLM: 8404176
Informations de publication
Date de publication:
2022
2022
Historique:
pubmed:
31
8
2021
medline:
21
12
2022
entrez:
30
8
2021
Statut:
ppublish
Résumé
An unknown coronavirus that emerged sometime at the end of 2019 in China, the novel SARS-CoV-2, now called COVID-19, has spread all over the world. Several efforts have been made to prevent or treat this disease, though not with success. The initiation of COVID-19 viral infection involves specific binding of SARS-CoV-2 to the host surface of the receptor, ACE2. The ACE2- SARS-CoV-2 complex then gets transferred into the endosomes where the endosomal acidic proteases cleave the S protein present in SARS-CoV-2, activating its fusion and release of the viral genome. We have carried out detailed and thorough
Identifiants
pubmed: 34455932
doi: 10.1080/07391102.2021.1960892
doi:
Substances chimiques
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Peptidyl-Dipeptidase A
EC 3.4.15.1
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM